HDAC9 and Huntington disease: Treatment with HDACi 4b, a histone deacetylase (HDAC) inhibitor compound that inhibits the activity of HDAC1 and HDAC3, ameliorated disease symptoms of N171-82Q (Table A1) HD mice [66] and also caused transgenerational phenotypical effects, i.e., milder cognitive and motor symptoms in the first filial (F1) generation of treated mice [65].